Clinical Trial Update: Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 single ascending dose study of the anti-IL-7 receptor alpha monoclonal antibody GSK2618960 in healthy volunteers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Diseases

Drugs mentioned

• GSK2618960 (GSK2618960)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Autoimmune Diseases | Phase 1 | Status: COMPLETED